Redpin Therapeutics operates at the intersection of biotechnology and neuroscience, focusing on the development of chemogenetic therapies. The company leverages pioneering research to create a platform that uses anti-smoking drugs to control neurons. This innovative approach has potential applications in both research and clinical settings. Redpin Therapeutics primarily serves pharmaceutical companies, research institutions, and healthcare providers. The market it operates in is the rapidly growing field of gene therapy and neurotechnology. The business model revolves around licensing its technology, partnering with pharmaceutical companies for drug development, and providing specialized research services. Revenue is generated through licensing fees, research grants, and collaborative agreements.

Keywords: chemogenetics, neuroscience, biotechnology, gene therapy, neurotechnology, anti-smoking drugs, neuron control, pharmaceutical partnerships, research services, clinical applications.